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Both rare and common genetic variants contribute to autism
in the Faroe Islands
Claire S Leblond 1,2,3,4, Freddy Cliquet 1,2,3,4, Coralie Carton1,2,3,4, Guillaume Huguet1,2,3,4, Alexandre Mathieu1,2,3,4, Thomas
Kergrohen1,2,3,4, Julien Buratti1,2,3,4, Nathalie Lemière1,2,3,4, Laurence Cuisset5, Thierry Bienvenu5,6, Anne Boland7, Jean-François
Deleuze7, Tormodur Stora8, Rannva Biskupstoe9, Jónrit Halling10, Guðrið Andorsdóttir9, Eva Billstedt11, Christopher Gillberg1,8,11,12 and
Thomas Bourgeron1,2,3,4,11
The number of genes associated with autism is increasing, but few studies have been performed on epidemiological cohorts and in
isolated populations. Here, we investigated 357 individuals from the Faroe Islands including 36 individuals with autism, 136 of their
relatives and 185 non-autism controls. Data from SNP array and whole exome sequencing revealed that individuals with autism had
a higher burden of rare exonic copy-number variants altering autism associated genes (deletions (p= 0.0352) or duplications (p=
0.0352)), higher inbreeding status (p= 0.023) and a higher load of rare homozygous deleterious variants (p= 0.011) compared to
controls. Our analysis supports the role of several genes/loci associated with autism (e.g., NRXN1, ADNP, 22q11 deletion) and
identiﬁed new truncating (e.g., GRIK2, ROBO1, NINL, and IMMP2L) or recessive deleterious variants (e.g., KIRREL3 and CNTNAP2)
affecting autism-associated genes. It also revealed three genes involved in synaptic plasticity, RIMS4, KALRN, and PLA2G4A, carrying
de novo deleterious variants in individuals with autism without intellectual disability. In summary, our analysis provides a better
understanding of the genetic architecture of autism in isolated populations by highlighting the role of both common and rare gene
variants and pointing at new autism-risk genes. It also indicates that more knowledge about how multiple genetic hits affect
neuronal function will be necessary to fully understand the genetic architecture of autism.
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INTRODUCTION
Autism spectrum conditions (ASCs; henceforth ‘autism’)
are diagnosed in 1–2% of the population worldwide and are
characterized by atypical social communication and the presence
of restricted interests, as well as stereotyped and repetitive
behaviors. Individuals with autism can also suffer from other
conditions including intellectual disability (ID), attention-deﬁcit
hyperactivity disorder (ADHD), anxiety, depression, epilepsy,
motor control difﬁculties, tics, sleep disorders, or gastrointestinal
problems.1 The heritability of autism is very high2 and molecular
genetic studies revealed that the genetic risk for autism is shaped
by a combination of rare and common variants.3–5 Thus, the
genetic susceptibility to autism can vary from one individual to
another. In some cases, a single de novo causative variant can be
detected. On the contrary, in some cases, the genetic architecture
is more complex and involves thousands of common genetic
variants, each one with low impact but collectively increasing the
susceptibility to autism. Most of our knowledge on the genetics of
autism comes from studies on unrelated individuals with autism
who do not share a recent common ancestor. Several studies
investigated families with autism from countries where consan-
guinity is high,6 but the genetic architecture of autism in isolated
populations remains largely unknown.
The Faroe Islands is an archipelago located in the North Atlantic
Ocean, halfway between Norway, Iceland, and Scotland (Fig. 1a).
The population (approximately 49,000 inhabitants) was founded in
the 9th century by a small number of emigrants from Norway. The
population remained at a small size for centuries until it
experienced a rapid expansion in the 1800s. Previous genetic
studies indicated that individuals from Scotland, Norway, Sweden,
Ireland, Iceland, and British Isles have signiﬁcantly contributed to
the current gene pool of the Faroese population.7,8
We previously showed that the prevalence of autism in the
Faroe Islands (0.94% of the population9–11) was similar to many
other western countries. In this study, we ascertained the genetic
proﬁle of 357 individuals including an epidemiological cohort of
36 individuals with autism born between 1985 and 1994 (Fig. 1
and S1 Fig), their relatives (n= 136) and a group of 185 controls.
We ﬁrst investigated the known causes of autism and then
identiﬁed new candidate genes. We also estimated the impact of
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inbreeding and the load of deleterious homozygous variants on
the risk of autism. Finally, both rare and common genetic variants
were used to stratify individuals with autism and to compare their
genetic and clinical proﬁles.
RESULTS
The genetic diversity in the Faroe Islands
A total of 67 children and adolescents with autism were detected
in a total population study of individuals aged 8–17 years living in
the Faroe Islands and born between 1985 and 1994.9,10 Thirty-six
of the 67 individuals (54% of the total group) signed (or had
parents who signed) informed consent forms and were included
in the genetic study. Participants and non-participants in the
genetic study were similar in terms of gender and cognitive
abilities (S1 Fig). In addition, we collected DNA from 136 of their
relatives and from 185 “non-autism” controls. The genetic proﬁle
included a high-density Illumina SNP array interrogating >4.3
millions of single nucleotide polymorphisms (SNPs) and a whole
exome sequencing (WES) to discover new variants. Using
identical-by-state (IBS) genomic distance (see Methods), we ﬁrst
compared the population structure of individuals from the Faroe
Islands with worldwide populations (Fig. 1b). All individuals were
clustered in the Faroese population with the exception of seven
controls who were removed from the analyses. Using admixture,
we showed that individuals from the Faroe Islands have
their genome in majority constituted from “European component”
(S2 Fig). As expected from the demographic history, individuals
from the Faroese population displayed a higher degree of
inbreeding compared with other world populations (Fig. 1c and
S3 Fig). The only population from the 1000 genomes project that
was more inbreed than the Faroese population was the Peruvian
from Lima.
Contribution of de novo variants
We ascertained the burden of de novo variants since they are key
players in the genetics of autism.12 The de novo variants were
identiﬁed for 31 independent families including 28 individuals
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Fig. 1 Genetic background of the Faroese population. a Geographic localization of the Faroe Islands. b Multidimensional scaling plots (MDS)
of genome-wide identity by state (IBS) pairwise distances between 1000 Genomes and Faroese populations. Each dot represents an individual
and the distance between two dots corresponds to genetic distance based on genome-wide pairwise IBS calculations. c Degree of inbreeding
across 1000 Genomes and Faroese populations. The inbreeding coefﬁcients of the Faroe non-autism control individuals (n= 176) were
compared to the 1000 Genomes populations. The 26 populations from 1000 Genomes project are described in S1 Appendix. Logarithmic
scale was used for y-axis
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with autism and 45 siblings for whom DNA of both parents was
available (see Clinical notes in S1 Appendix for the pedigrees). The
combined analysis of genotyping and WES data revealed the
presence of de novo chromosomal abnormalities and exonic
copy-number variants (CNVs) in 3 out of 26 individuals with autism
(11.5%) and 1 out of 43 siblings (2.3%). One female PN400129 had
a trisomy of chromosome 21 and was diagnosed with autism, ID
and Down syndrome (S4 Fig and S1 Table). One female PN400533
with atypical autism without ID carried a de novo 2.9 Mb deletion
on chromosome 22 causing 22q11.2 deletion syndrome (also
known as DiGeorge/VeloCardioFacial syndrome). A male
PN400115 with atypical autism without ID carried a de novo
425.5 kb deletion removing the ﬁrst six exons of the NRXN1α. We
also found a 91.4 kb deletion removing all exons of ADNP in a
male with autism and ID (PN400125). The deletion was not found
in the mother and was most likely de novo, but father’s DNA was
not available and none of the SNPs within the deletion were
informative to conﬁrm the de novo status of the deletion. The de
novo CNV observed in a sibling (PN400170) was a duplication of
782 kb affecting 5 genes (CNPY1, DPP6, EN2, HTR5A, INSIG1 and
PAXIP1).
Using the WES data, we detected the presence of de novo
single nucleotide variants (SNVs) and small insertions/deletions
(indels)(S2 Table). Overall, the rate of de novo exonic SNV/indels
was similar to other studies13 and was not different in individuals
with autism (0.93) and their siblings (0.96). The variants were
considered as probably deleterious when they were likely gene
disruptive (LGD, for example stop gain or frame shift variant) or
missense events with a combined annotation dependent deple-
tion (CADD) score > 30 (MIS30).14 There was also no signiﬁcant
increase in the rate of de novo deleterious variants in individuals
with autism compared to their siblings (two-sided Fisher’s exact
test: 9/31 (29%) MIS30+ LGD SNV in autism, 6/49 (12%) MIS30+
LGD SNV in sibling; p= 0.08, OR= 2.89, CI 95% [0.8–11.25]) and no
signiﬁcant enrichment in genes associated with autism (SFARI
genes15) or expressed in the brain (Brain genes, see methods for
gene selection). Nevertheless, several deleterious variants were
identiﬁed in known genes for autism (MECP2) or compelling
candidate genes (RIMS4, KALRN, PLA2G4A) (S5 Fig). Clinical details
on the individuals with autism carrying those variants are available
in the S1 Appendix.
Contribution of rare CNVs and SNVs/indels variants
Global rare CNV analysis was performed using the XHMM CNV
calling from WES data and the overall burden of rare exonic CNVs
(frequency < 0.01) was higher in individuals with autism compared
to controls for duplications (pnominal= 0.005) (Fig. 2 and S3 Table).
The burden of deletions was higher for autism-associated genes
listed in the SFARI database (pnominal= 0.035) and for genes
intolerant to loss-of-function variant (pLI > 0.9)16 (pnominal= 0.014).
For duplications, SFARI genes or genes expressed in the brain
were more frequently duplicated in individuals with autism
compared to controls (“SFARI” pnominal= 0.035 and “Brain” pnominal
= 0.003, pcorrected= 0.036, 12 tests). Most of these differences
however do not survive corrections for multiple tests and we had
no signiﬁcant difference between individuals with autism and
their siblings. Among the SFARI genes affected by the CNVs, we
identiﬁed a 58 kb maternal inherited deletion including the
IMMP2L, a 2 Mb paternal inherited duplication on the pseudo-
autosomal region 1 including SHOX and ASMT, and a 39 kb
maternal inherited duplication of TBL1XR1 (S3 Table).
Our global analysis was restricted to CNVs affecting exons, but
using CNV called from SNP dataset we identiﬁed an additional
large 357 kb duplication within intron 5 of the NLGN1 gene and
covering a long NLGN1 antisense noncoding RNA that was
paternally inherited in a female (PN400102) with autism and no
ID. There was no such rare intronic CNVs in the SFARI genes in
siblings and controls.
We then run single variant and gene-wise association tests from
rare SNV/indels (MAF < 5%) and none of associations were
genome-wide or gene-wide signiﬁcant (S6-7 Fig and S4-S7 Tables).
We found truncating variants affecting several SFARI genes (e.g.,
PRODH, ERBB4, GRIK2, ROBO1, RBMS3, and IMMP2L; S6 Fig. and S7
Table), but the number of patients carrying these variants was too
low to detect a signiﬁcant association.
Founder effect
As the Faroe population originates from a small number of
founders, speciﬁc changes in allele frequencies through genetic
drift could contribute to the risk of autism. In order to detect a
founder effect, we investigated the contribution of the common
variants (MAF > 5%) using genome wide association studies
(GWAS) in cases and controls using three models (allelic, recessive
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Fig. 2 Rare CNVs in Faroese individuals. Rare copy-number variant (CNV) analysis among gene-set lists within Faroe individuals (XHMM CNV
calling from WES and CNV frequency < 0.01 in controls). The number of exonic CNV carriers altering any gene or gene-set lists (SFARI genes,
pLI > 0.9 genes and Brain genes, see Materials and Methods section) were compared between individuals with autism, siblings and controls
(one-sided Fisher’s exact test: nautism= 36, nsib= 28, ncontrols= 107, pCNV_loss_SFARI= 0.035, ORCNV_loss_All_SFARI= 6.56; pCNV_loss_pLI>0.9= 0.014,
ORCNV_loss_pLI>0.9= 13.25; pCNV_gain_All_genes= 0.005, ORCNV_gain_All_genes= 3.09; pCNV_gain_SFARI= 0.035, ORCNV_gain_All_SFARI= 6.56; pCNV_gain_Brain=
0.003*, ORCNV_gain_All_Brain= 5.61; *indicates the one withstanding Bonferroni correction for 12 tests; for families with multiple siblings, only
one sibling was kept (closest on age)). Error bars represent conﬁdence interval
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and dominant) and a burden/collapsing test that aggregates the
variants located in a gene. Neither GWAS nor gene-based analysis
revealed a speciﬁc variant that pass genome wide signiﬁcance.
The absence of a statistically signiﬁcant variant shared by the
patients indicates that, within this sample, we could not detect a
founder effect for the genetic risk of autism in the Faroe Island.
The results of the GWAS and gene-based analysis are presented in
S6 and S8-9 Figs and S9-S11 Tables.
Contribution of recessive variants
Since inbreeding increases the risk for individuals to carry
homozygous deleterious variants, we ﬁrst compared the inbreed-
ing coefﬁcient of the individuals with autism, their relatives and
controls. Patients (p= 0.023), as well as their siblings (p= 0.016)
had a higher inbreeding coefﬁcient compared with controls
(Fig. 3a). Remarkably, even after correction for inbreeding, we
found that individuals with autism were carrying more deleterious
AGBL3
COL9A1
MEP1B
MUC22
HLA-DRB5
HRNR
KIR3DL1
PKD1L2
HLA-DQB1
ACACAb
CNTNAP2a,c
GANC
LXN
MTMR9c
OR2T27
PEX6
TCP11
TRIM31
UMOD
ZNF212c
ARL6IP6
CCDC90Bc
CPXM1
DHRS4L2
KIRREL3a,b
MDP1
P2RX2
PREX2
RUNX1
RYR1
SOS2b
URB1
C10orf68
CHD1a,b
CSADc
FAM101B
FASTKD1
KIF13Ab
MACF1b,c
NSUN7
PDGFRL
SMCR7L
SSTR1
TRAK1c
a SFARI Genes
b Genes with pLI >= 0.9 
c Genes expressed in the brain >1SD
Autism
(n=36)
Control
(n=107)
Sibling
(n=53)
a b
c
PN400558 PN400555
PN400528 PN400556PN400557
KIRREL3 p.R562L
TECTA p.N687K
0/1     0/1 0/1     0/1
0/0     0/0 1/1     1/1 0/1     0/1
IgD1 IgD2 IgD3 IgD4 IgD5
transmembrane
domain
extracellular
domain
cytoplasmic
domain
Human
Rhesus
Mouse
Dog
Zebrafish
MATIVAFCCARSQRNLKGVVSAKND
MATIVAFCCARSQRNLKGVVSAKND
MATIVAFCCARSQRNLKGVVSAKND
MATIVAFCCARSQRNLKGVVSAKND
MGTIGAFCCTRSQRNLKGVVSAKND
562
R562L
KIRREL3
N687K
Human
Rhesus
Mouse
Dog
Zebrafish
687
LCEEGGDVYCFNKTCGSGEVCAVED
LCEEGGDIYCFNKTCSSEEVCAVED
LCEEGGDVYCFNKTCRSGEVCAVED
LCEEGGDVYCFNKTCRSGEVCAVED
VCGPAGEVKCFNDSCGEGEVCAAEV
TECTA TIL TILa
d
ABHD12B
ABHD16B
ADORA3a
C19orf25
CEACAM7
DRD4
EDEM3
FAM160B2
FAM209B
GPR113
HKDC1
IFT122
IFT74
KIAA0355
LOC101928451
LRRFIP2
MCCC1c
MFAP5
MICAL1c
MICAL2c
MYH7B
NUDT17
OPRK1
PCK2
POLR3C
ST8SIA6
TPH1
UGT2B17
WDR62
YPEL1c
PN400583 PN400580
PN400581 PN400582PN400579
CNTNAP2 p.E680K
PEX6 p.R601Q
0/1     0/1 0/1     0/1
1/1     1/1 1/1     0/1 0/1     1/1
e
AAA AAA
Human
Rhesus
Mouse
Dog
Zebrafish
FPHELEVPALSEGQRLSILRALTAHLPLG
FPHELEVPALSEGQRLSILRALTAHLPLG
FPHELEVPVLSEAQRLSILQALTAHLPLG
FPHELEVPVLSEGQRLSVLQALTAHLPLG
-----------------------------
601
PEX6
R601Q
LamG
FA5/8C
Prokar.
Fibr.
EGF
LamGLamGLamG
Human
Rhesus
Mouse
Dog
Zebrafish
SASMDQISAITDSAEYCEQYVSYFCKMSR
SASMDQISAITDSAEYCEQYVSYFCKMSR
SASMDQISAITSSAEYCEQYVSYFCRMSR
SASMDQISAVTSSAEHCEQYVSYFCKMSR
SASMEQISAITNSAEHCEQHVSYACRMSR
680
CNTNAP2
E680K
EGF
C
on
tro
l
A
ut
is
m
S
ib
lin
g
0.00
0.05
0.10
0.15
0.20
0.03
0.03
Pr
op
or
tio
n 
of
 in
di
vi
du
al
s 
w
ith
 
a 
SN
V 
in
 li
st
s 
a , 
b  o
r c
Control Autism Sibling
0.00
0.02
0.04
0.06
0.08
0.10
in
br
ee
di
ng
 c
oe
ffi
ci
en
t
0.023*
0.016*
0 1 2 3 4 5
Nb of LGD+MIS30 homozygous SNV
0.0
0.2
0.4
0.6
0.8
Pr
op
or
tio
n 
of
 in
di
vi
du
al
s Control
0 1 2 3 4 5
Autism
0 1 2 3 4 5
Sibling
69
21
7
1
15
13
5
2 1
28
13
7
3
0.011*
C.S. Leblond et al.
4
npj Genomic Medicine (2019)     1 Published in partnership with CEGMR, King Abdulaziz University
homozygous variants (LGD, MIS30, gnomAD MAF < 1%) than
controls (p= 0.011; Fig. 3b and S8 Table). Genes carrying
deleterious homozygous variants in affected individuals were
signiﬁcantly enriched in the combined gene-set lists (SFARI+ pLI
> 0.9+ Brain genes) compared to controls (p= 0.03; Fig. 3c).
In one female individual PN400528 (inbreeding coefﬁcient F=
0.04), we found a KIRREL3 homozygous damaging missense
variant (p.R562L, absent in gnomAD) affecting a conserved residue
in the cytoplasmic domain of this synaptic adhesion molecule17
listed in SFARI and associated with neurodevelopmental dis-
orders18 (Fig. 3d). Interestingly, this female with autism and
a normal IQ was also homozygous for another deleterious variant
(p.N687K, rs139165033, gnomAD European allele frequency=
0.003165) affecting TECTA, a SFARI gene associated with autism
and deafness.19
In another family, the male PN400579 (inbreeding coefﬁcient F
= 0.1) was homozygous for two variants affecting CNTNAP2 and
PEX6 (Fig. 3e). Recessive CNTNAP2 variants are associated with Pitt-
Hopkins like syndrome 1 and cortical dysplasia-focal epilepsy
syndrome (MIM #610042). The CNTNAP2 p.E680K variant
(rs368905425, gnomAD European allele frequency= 0.0001979)
affects a highly conserved amino acid within the ﬁbrinogen
domain of the protein. Recessive PEX6 variants are associated with
Heimler syndrome 2, a recessive peroxisome disorder character-
ized by sensorineural hearing loss, amelogenesis imperfecta and
nail abnormalities, with or without visual defects (MIM #616617).
The homozygous variant p.R601Q (rs34324426, gnomAD Eur-
opean allele frequency= 0.004849) carried by the male with
autism can be considered pathogenic since it was previously
detected in several independent patients diagnosed with Heimler
syndrome 2.20 Details on the clinical proﬁles of the families are
available in S1 Appendix.
Estimation of the genome-wide polygenic score
We ascertained the autism genome-wide polygenic score (GPS-
autism) for each individual. The GPS-autism was calculated using
PRSice-2 from a previous GWAS using over 16,000 individuals with
autism4 who do not overlap with this sample. GPS analysis
requires the estimation of a P-value signiﬁcance threshold in order
to include only variants exceeding this P-value threshold in the
GPS calculation. Here, the best ﬁt P-value threshold was 0.2
corresponding to a squared correlation coefﬁcient (R2) of 0.036
(S10 Fig). After correction for ancestry and inbreeding, we found a
signiﬁcantly higher GPS-autism in individuals with autism
compared to controls (p= 0.017; Fig. 4a). Remarkably, in the
autism group, the GPS-autism was signiﬁcantly higher
in individuals without ID compared to those with ID (p= 0.039,
Fig. 4b). These results should be however taken with care since our
number of cases is small and we could not detect signiﬁcant
differences between cases and controls when P-value thresholds
of 0.05 or 0.1 were chosen to compute the GPS.
Genetic stratiﬁcation of autism in the Faroe Islands
In order to stratify individuals with autism, we used the number of
rare deleterious variants in SFARI genes (including CNVs) and the
GPS-autism estimated from the common variants (Fig. 5). This
hierarchical clustering is an illustration on how similar are some
patients regarding their genetic proﬁle. We found three main
clusters. The ﬁrst one comprised eleven individuals with high GPS-
autism and high burden of deleterious variants in SFARI genes. In
this cluster, only one individual had ID (PN400115 carrying the de
novo NRXN1 deletion). In the second cluster, fourteen individuals
had low GPS-autism and low burden of SFARI genes deleterious
variants. In this cluster 50% of the individuals had ID. In the third
cluster, nine individuals had high GPS-autism, but low burden of
SFARI deleterious variants. In this cluster, 33% of the individuals
had ID and it includes two individuals with autism with epilepsy
and two individuals who were preterm babies.
DISCUSSION
In this study, we investigated a group of individuals with autism
that has two distinctive features. First, the group is representative
of a general population cohort of all young people living in the
Faroe Islands at one point in time. Secondly, the Faroese
population has a more homogeneous genetic background
compared to most other populations.
We found a subset of individuals carrying strongly deleterious
variants (some of which appeared de novo) affecting single genes
or chromosomal regions. The chromosomal abnormalities
included one trisomy 21 and one 22q11 deletion (causing Down
and 22q11.2 deletion syndromes, respectively). This was not
surprising to ﬁnd such known genetic disorders in an epidemio-
logic cohort since the prevalence of autism in individuals
diagnosed with these syndromes is higher than in the general
population (16–37% for Down syndrome,21 and 23–50% for
DiGeorge/VeloCardioFacial syndrome deletion22). We also
revealed new variants in known autism-risk genes (ADPNP, NRXN1,
NINL, MECP2) and identiﬁed new compelling candidate genes such
as KALRN, PLA2G4A, and RIMS4.
KALRN codes for a guanine nucleotide exchange factor (GEF)
expressed in neuronal tissue during embryonic development23
and has been associated with schizophrenia risk through
association analysis, and, postmortem analyses of cortical KALRN
mRNA and protein levels within individuals with autism.24 KALRN is
strongly homologous to TRIO, a gene previously associated with
autism.25 It is also a binding partner of the Huntingtin and a
regulator of structural and functional plasticity at dendritic spines.
The de novo variant (p.N2024D; CADD= 26.7) was never observed
in the general population and affects a key amino acid of the GEF
domain conserved through evolution. The male individual
(PN400117) carrying this de novo KALRN variant has no ID.
Fig. 3 Genetic recessive mutations in Faroese individuals with autism. a Distribution of the inbreeding coefﬁcient in Faroese individuals (one-
sided Mann Whitney U-test: nautism= 36, ncontrol= 176, nsibling= 30; Ucontrol.vs.autism= 2500, pcontrol.vs.autism= 0.023; Ucontrol.vs.sibling= 1995,
pcontrol.vs. sibling= 0.016; sibling inbreeding coefﬁcients were averaged out by family; P-values were adjusted for principal component ancestry
(3 principal components); *indicates the one withstanding Bonferroni correction for two paired comparisons). b. Number of rare LGD+MIS30
homozygous mutations carried per individual (one-sided Mann Whitney U-test: nautism= 36, ncontrol= 107, nsibling= 28; Ucontrol.vs.autism= 1305,
pcontrols.vs.autisms= 0.011; sibling number of rare SNV were averaged out by family; P-values were adjusted for inbreeding; * indicates the one
withstanding Bonferroni correction for two paired comparisons). c Venn diagram of the genes carrying the variants from b. Genes names are
in bold and annotated when they are part of our gene-set lists (SFARI genes, pLI > 0.9 genes and Brain genes, see methods section). The plot
on the right shows the proportion of individuals in each category carrying at least one mutated gene in our gene-sets lists (Fisher’s exact test:
pcontrols.vs.autisms= 0.03; pcontrols.vs. siblings= 0.03). Error bars represent standard error. d and e are describing two speciﬁc families carrying
multiple variants. “0” and “1” refer to wildtype or mutated allele, respectively. The localizations of the variants are indicated along the proteins
and alignments throughout species showed the strong conservation of the altered amino acids. Nb Number, SNV Single Nucleotide Variant,
LGD likely gene disruptive, MIS30 missense variants with CADD score ≥30, IgD immunoglobulin domain, TIL Trypsin Inhibitor-like, FA5/8 C
Coagulation factor 5/8 type C domain, LamG Laminin G domain, EGF epidermal growth factor like domain, Fibr. Fibrinogen, alpha/beta/
gamma chain, C-terminal globular domain, AAA ATPases associated domains
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(ID) and the cases with ID (one-sided Mann Whitney U-test: nautism-with-ID= 12, nautism-without-ID= 24; UID.vs.no-ID= 91, pID.vs.no-ID= 0.039; Q1no-ID
= 0.0010, Q2no-ID= 0.0012; Q3no-ID= 0.0013, Q1ID= 0.0008, Q2ID= 0.0009, Q3ID= 0.0012). The GPS was calculated using PRSice-2 (see
methods section, P-value threshold of 0.2 and R2 of 0.036). P-values were computed on data adjusted for principal component ancestry and
for inbreeding
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PLA2G4A codes for the cytosolic phospholipase A2α that
catalyzes the hydrolysis of membrane phospholipids to produce
arachidonic acid. Mice lacking Pla2g4a display abnormalities in
neuronal maturation (narrow synaptic cleft)26 and long-term
potentiation. The de novo variant (p.R485C; CADD= 35) has never
been observed in the general population and is predicted as a
deleterious variant falling in the catalytic domain of the protein.
The female PN400102 carrying this de novo variant has no ID.
RIMS4 codes for a presynaptic protein that plays a key role in
dendritic and axonal morphogenesis.27 RIMS1 and RIMS3 have
already been associated with autism.28 The individual (PN400137)
carrying the de novo RIMS4 stop variant (p.Y204*; CADD= 38) has
a normal IQ (Performance IQ= 108, Verbal IQ= 116). The variant is
predicted to truncate the last quarter of the protein and was never
observed in the general population. Interestingly, RIM proteins
interact with voltage-dependent Ca(2+) channels (VDCCs) and
suppress their activity at the presynaptic active zone to regulate
neurotransmitter release. Knockdown of gamma-RIMs (RIMS3 and
RIMS4) attenuated glutamate release to a lesser extent than that of
alpha-RIMs (RIMS1 and RIMS2). As a consequence, competition
between alpha- and gamma-RIMs seems to be essential for
modulating the release of glutamate at the synapse. We can
therefore hypothesize that the de novo RIMS4 truncating stop
variant perturbs the ﬁne-tuning of glutamatergic release at the
synapse and contributes to autism.
In genetic isolates, it is frequent to observe an increased
frequency of diseases due to the presence of deleterious variants
that were present in the genomes of the small group of migrants
who settled the population. In the Faroe Islands, this “founder
effect” was documented for several genetic diseases such as
Bardet-Biedl syndrome,29 cystic ﬁbrosis,30 3-Methylcrotonyl-CoA
carboxylase deﬁciency, glycogen storage disease type IIIA31 and
retinitis pigmentosa.32 We conﬁrmed that inbreeding in the Faroe
Island is higher than expected compared with other populations.
The median inbreeding coefﬁcient is F= 0.015 ± 0.001 in the
control sample and is similar to the one reported by Binzer and
colleagues (2014) in their study on multiple sclerosis in the Faroe
Islands (F= 0.018).33 This level of inbreeding corresponds
approximately to children from parents with a second-cousin
relationship (F= 0.016). We also observed that individuals with
autism from the Faroe Islands have a signiﬁcantly higher level of
inbreeding and burden of recessive deleterious variants compared
to their geographically matched controls. The homozygous
deleterious variants carried by individuals with autism were
enriched in genes included in our list of genes of interest (e.g.,
high intolerance for loss of function variants, expressed in the
brain and previously associated with autism). However, one
should note that the increased probability for having autism
due to inbreeding in the Faroe Islands is relatively small (Fautism=
0.0212; Fcontrols= 0.0187; Cohen’s d= 0.43; p= 0.023).
In contrast to other genetic conditions, we could not detect a
founder effect for autism in the Faroe Islands. Moreover, the loci
identiﬁed in our study do not overlap with those detected in a
previous genetic microsatellite association study in the Faroese
population pointing at regions on 2q, 3p, 6q, 15q, 16p, and 18q.34
We also found no overlap between the variants identiﬁed in our
study and those found in Faroese individuals with autism
diagnosed with panic35 or bipolar disorders. This absence of a
founder effect is also in agreement with the epidemiological
observation that the prevalence of autism in the Faroese
population is not higher compared to more outbred populations.
Overall, our study conﬁrms that both rare and common genetic
variants contribute to the susceptibility to autism. Although, we
identiﬁed previously known genetic causes for autism and pointed
at new compelling candidate genes, we also showed a contribu-
tion of the common variants illustrated by the higher GPS-autism
in individuals with autism (especially those with no ID) compared
to controls. To date, in the literature, very few genes are identiﬁed
in individuals diagnosed with autism and intact general intelli-
gence. Based on the genes previously reported (NLGN3, NLGN4X,
duplication of SHANK3) and the genes found in this study (RIMS4,
KALRN, PLA2G4A), it seems that the proteins involved in autism
without ID converge to different parts of the post-synapse and
pre-synapse rather than to pathways such as gene regulation and
chromatin remodeling, but this has to be conﬁrmed on larger
cohorts. Indeed, the main limitation of our study is the small
number of individuals with autism. Several LGD variants affecting
autism-risk genes such as GRIK236 or ASMT37 were found
exclusively or more frequently in individual with autism compared
to controls, but a replication cohort is necessary to conﬁrm the
contribution of these variants in the susceptibility to autism in the
Faroe Islands.
In summary, this study improves our knowledge on the genetic
architecture of autism in epidemiological cohorts and in genetic
isolates by showing that the contribution of both rare and
common gene variants to autism can be detected in small, but
genetically homogeneous populations. It also provides new
compelling candidate genes and reveals that high inbreeding
and high load of homozygous deleterious variants can be a risk
factor for autism. Such combined analysis investigating both rare
and common gene variants might represent a useful framework to
investigate, from groups to individuals, the complex genetic
architecture of autism.
METHODS
Preprint publication
The article was previously published as a preprint in bioRxiv (BIORXIV/
2018/363853; https://doi.org/10.1101/363853).
Ethics statement
This study was approved by the IRB of the “Institut Pasteur” of Paris
(IRB00006966 Institut Pasteur, approval 2010-003). All participants over 18
and parents of the participants under 18 provided written informed
consent to take part in the study (for more details see S1 Appendix).
Genotyping
The cohort available for the genotyping is shown in Fig. 1 and S1 Fig. It
includes 36 individuals with autism, 208 controls, 132 close relatives of the
individuals with autism (61 siblings, 3 half-siblings and 68 parents) and 9
close relatives from the controls. DNA was extracted from blood
leukocytes. The genotyping was performed at the “Centre National de
Recherche en Génomique Humaine (CNRGH)” using the Inﬁnium
IlluminaOmni5-4 BeadChip (>4.3 millions of markers) from Illumina.
Sample quality controls such as Sex check (based on the X chromosome
homozygosity rate), Mendel errors (transmission errors within full trios) and
Identity By State (IBS, see section below) were performed using PLINK
1.90.38
Population genetic structure
Prior to population genetic structure analysis, the genotyping dataset of
the Faroese cohort was merged to the 1000 Genomes project dataset
(ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20130502/). Genotyping
rate and the total number of markers after the merge was ∼ 0.93% and
∼ 4.27 millions, respectively. For the estimation of the ancestry, SNPs with
genotyping call rate < 100%, failing Hardy Weinberg equilibrium test (p <
10−3) or on sex chromosomes were ﬁltered out of the merged genotyping
dataset (∼ 2.60 million markers passed ﬁlters). Genome-wide pairwise IBS
calculations and Multidimensional scaling (mds) analysis on genome-wide
IBS pairwise distance matrix was calculated using PLINK 1.90. IBS values
have been calculated for 376 individuals from Faroe Islands and 2504
individuals from 1000 Genomes project (26 populations; see S1 Appendix)
with the following calculation: 1−(0.5 × IBS1+ IBS2)/N; N is the number of
tested markers; IBS1 and IBS2 are the number of markers for which one
pair of individuals share either 1 or 2 identical allele(s), respectively. Out of
the 376 individuals, 32 individuals were removed from further analyses,
including 7 ancestry outliers in controls, 9 siblings of controls, one swap
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and 15 control individuals involved in pairs with IBS score higher than 0.9.
For all studies, we used the ﬁrst three principal components to adjust for
population stratiﬁcation.
For the estimation of the inbreeding coefﬁcient, SNPs with genotyping
call rate < 95%, minor allele frequency < 0.05, strong linkage disequilibrium
r > 0.5 or failing Hardy Weinberg equilibrium test (p < 10−6) were ﬁltered
out of the Faroe SNP genotyping dataset. All homozygosity analyses were
performed with Plink 1.09 on autosomes including identiﬁcation of Runs
Of Homozygosity (ROH) and Inbreeding coefﬁcients calculation. For ROH
detection, a threshold of 50 consecutive homozygous SNPs with a
minimum density of 1 SNP/5000 kb and no minimum length was used
following Gazal et al.’s guidelines.39 We allowed no heterozygous markers
in the 50 SNPs-window. Inbreeding coefﬁcients were calculated by
estimating the proportion of the autosomal genome that is in ROH. This
method was proposed by McQuillan and al (2008) and has been shown to
be the most reliable, especially with small sample size.40 Faroe inbreeding
coefﬁcients were compared to inbreeding coefﬁcient of the 1000 genomes
project populations.
Genome-wide association study (GWAS)
Prior to association analyses, SNPs with genotyping call rate < 90%, minor
allele frequency < 0.05 or failing Hardy Weinberg equilibrium test (p <
10−6) were ﬁltered out of the Faroe SNP genotyping dataset. The global
genome wide genotyping call rate of all the individuals was superior to
90%. A total of 1,690,491 variants and 212 independent individuals
(including 36 cases and 176 controls) passed these ﬁlters. Allelic, recessive
and dominant GWAS were performed with Plink 1.09 using Chi-squared
statistics. Manhattan and Quantile-Quantile (Q-Q) plots were generated
using R. Gene and gene-set (including SFARI, pLI > 0.9 and Brain gene lists)
analyses were performed with MAGMA v1.06 using principal components
regression and linear regression models, respectively.
Genome-wide polygenic score (GPS) for autism
The computation of the GPS (also named PRS for polygenic risk score) was
performed with the tool PRSice241 on the SNP array data using as a
reference the PGC GWAS summary statistics.4 SNPs were not imputed since
we used high density arrays (over 4 million SNPs). Brieﬂy, GPS is calculated
as a weighted sum of the number of risk alleles carried by an individual,
where the risk alleles and their weights are deﬁned by the loci and their
measured effects as detected by a previous GWAS. GPS analysis requires
the estimation of a P-value signiﬁcance threshold in order to include in the
GPS calculation only variants below this P-value threshold. For our dataset,
PRSice2 with default parameters was used (except for the P-value
threshold for which a step of 0.01 was used) and deﬁned a P-value
threshold of 0.2 which gives us a R2 (squared correlation coefﬁcient) of
0.036 (S10 Fig).
Whole-Exome Sequencing (WES)
Blood leukocytes DNA from 286 individuals was enriched for exonic
sequences through hybridization SureSelect Human All Exon V5 (Agilent)
by the CNRGH. For 67 individuals for whom the available quantity of DNA
was low, we used a low-input protocol using only 200 ng of DNA
compared to 3 µg for the normal protocol. The captured DNA was
sequenced using a HiSeq 2000 instrument (Illumina). Coverage/depth
statistics have been used for quality control. We required that more than
90% of each exome had 10× coverage and more than 80% had 20×
coverage. Short read sequences were then aligned to hg19 with BWA
v0.7.8, duplicate reads were removed with PicardTools MarkDuplicates.
Reads with a global quality under 30 or a mapping quality under 20 were
excluded from the analysis. Variants were predicted using FreeBayes and
GATK42 with a minimum of 10 reads covering the position. VEP (using
RefSeq and Ensembl 91) was used to annotate the variants. We used the
GEMINI43 framework that automatically integrates the VCF ﬁle into a
database for exploring genetic variant for disease and population genetics.
Genetic variants were analyzed using GRAVITY, a Cytoscape plugin that we
designed for visualizing WES results using Protein-Protein Interaction
networks (http://gravity.pasteur.fr/). Since WES does not detect the FMR1
ampliﬁcation, 33 individuals with autism were tested for Fragile-X
syndrome using the AmplideXTM FMR1 PCR kit from Theradiag. No
individual were carrier of a “pre-mutation” or “full-mutation” of CGG
repeats in the 5’ UTR region of the fragile X mental retardation-1 (FMR1)
gene.
Copy-number variants (CNVs)
CNVs were identiﬁed from both SNP genotyping and WES data. Quality
controls were the following: call rate > 0.99, standard deviation of the Log
R ratio < 0.35, standard deviation of the B allele frequency < 0.08 and
absolute value of the wave factor < 0.05. CNVs were detected by both
PennCNV and QuantiSNP algorithms using the following ﬁlters: >= 3
consecutive probes, CNV size > 1 kb and CNV detection conﬁdence
score >= 15. CNV detections from PennCNV and QuantiSNP were merged
using CNVision.44 CNVs with CNVision conﬁdence score < 30, CNV size <
50 kb, overlap > 50% with segmental duplication or known large assembly
gaps (greater than 150 kb) or copy number= 2 in pseudo autosomal
regions (PARS) in males were ﬁltered out. CNV annotations were
performed using ANNOVAR45 and CNV frequencies in Faroese and in
database of genomic variant cohorts (DGV, http://dgv.tcag.ca/dgv/app/
home) were assessed using in house python scripts based on reciprocal
overlap in size >= 80%. CNV calling from Illumina genotyping data was
used only for segregation analysis across families. We also detected CNVs
from the WES sequencing data using the XHMM software.46 CNVs with
QSOME score < 90, number of targets < 5, or overlap > 50% with segmental
duplication or known large assembly gaps (greater than 150 kb) were
ﬁltered out. CNV annotations were performed using ANNOVAR45 and CNV
frequencies in Faroese were assessed using in house python scripts based
on reciprocal target overlap ≥50% and using only independent cases and
controls (n= 143). For the burden analysis of rare CNVs, only XHMM CNV
calling from WES data was used and CNVs with frequency > 0.01 were
ﬁltered out. De novo and inherited CNVs were validated by visual
inspection using SnipPeep (http://snippeep.sourceforge.net/).
Gene-set lists and prioritization of variants
Three gene-set lists were used: (i) “SFARI genes” (n= 990) that includes
genes implicated in autism15 (Simons Foundation Autism Research
Initiative gene database–https://gene.sfari.org/); (ii) “pLI > 0.9 genes” that
includes genes with strong probability of being loss-of function intolerant
(n= 3230); (iii) “Brain genes” that includes genes speciﬁcally or strongly
expressed (above 1 Standard Deviation) in fetal or adult human brain using
data from Su et al. (n= 3591).47
A combination of approaches was used to prioritize the genes and to
estimate the deleterious effect of a variant. We prioritized genes using
gene sets (SFARI genes, pLI >= 0.9 and Brain genes). We prioritized Likely
Gene Disruptive (LGD) variants (stopgains, splice site variants, frameshift
indels) over missense variants or synonymous variants. Additionally, we
used the CADD score14 (a CADD >= 30 means that the variants belong to
the 0.1% most deleterious variants) to assess the deleterious effect of
missense variants. Minor allele frequency (MAF) was estimated in the
general population from the gnomAD database. In order to ﬁlter out
common variants that was not listed in gnomAD, we also excluded variants
that were present in more than 15% of our Faroese control cohort. For the
detection of deleterious homozygous variants, we kept only LGD and
MIS30 with MAF < 1%.
Burden analysis
Rare variant association studies (MAF < 5%) were performed using EPACTS
v3.2.6 (https://genome.sph.umich.edu/wiki/EPACTS). Prior to association
analysis, variants identiﬁed by WES were ﬁltered using VCFtools (http://
vcftools.sourceforge.net/man_latest.html) with the following metrics:
minimum genotyping quality ≥30, min depth of coverage ≥ 10, maximum
of missing data ≤ 10, only bi-allelic sites and no site failing Hardy Weinberg
equilibrium test (p < 10−6). The annotation of the variants was done using
EPACTS and the variants included in the Gene-wise association analyses
were non-synonymous, essential splice site, normal splice site, start loss,
stop loss and stop gain variants. Logistic Score Test (“b.score” in S6 Table)
was used to test single variant association (nCases= 36; nControls= 107;
nVariants= 155,284). For Gene-wise tests, we used two approaches
(including nCases= 36; nControls= 107 and ngroups= 15,005): (i) collapsing
burden test using EMMAX (Efﬁcient Mixed Model Association eXpedited,48
“CMC-EMMAX” in S4 Table) and (ii) Optimal SNP-set sequence Kernel
Association Test (“SKAT-O” in S5 Table). The advantage of the CMC-EMMAX
is that this test is accounting for population structure and high relatedness
between individual (based on kinship matrix). The advantage of SKAT is
that this test is particularly powerful in the presence of protective and
deleterious variants and null variants. For both Gene-wise tests, a 10−6≤
MAF ≤ 0.05 was used.
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Statistical power of the analyses
All the statistical tests performed were one-sided since the objectives were
to identify some enrichments in autism participants. Achieved power and
necessary effect size (using Cohen’s d) to achieve a power of 0.8 was
computed using G*Power (http://www.gpower.hhu.de/). For CNVs (Fig. 2),
given our sample size, the post-hoc achieved power is 0.65 for CNV Loss in
all genes, and 0.93 for CNV Gain in all genes. The details on subsets of
genes are indicated in S12 Table and the sensitivity to detect effect sizes at
a statistical power of 0.8 is indicated in S13 Table. For inbreeding
coefﬁcient (Fig. 3a), an effect-size of d= 0.43 was observed. Given our
sample size, the post-hoc achieved power is 0.74. To achieve a power of
0.8, an effect-size of d= 0.47 was needed. For LGD+MIS30 rare
homozygous variants (Fig. 3b), the observed effect-size is d= 0.68. Given
our sample size, the post-hoc achieved power is 0.96. To achieve a power
of 0.8, an effect-size of d= 0.49 was needed. For GPS (Fig. 4a), the
observed effect-size is d= 0.45. Given our sample size, the post-hoc
achieved power is 0.77. To achieve a power of 0.8, an effect-size of d= 0.47
was needed. For GPS between individuals with and without ID (Fig. 4b), the
observed effect-size is d= 0.80. Given our sample size, the post-hoc
achieved power is 0.70. To achieve a power of 0.8, an effect-size of d= 0.92
was needed. For enrichment in de novo events for SNVs (Section
“Contribution of de novo variants” of the manuscript), given our sample
size, an effect size of d= 0.60 was required to achieve a power of 0.8.
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